MIRAMAR, FL, June 16, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB:STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that Charles Arnold, Stemtech’s Chairman and CEO, has received the Global Eagles Business Leader of the Year award.
The award was presented at a ceremony in Fort Lauderdale, Florida by Global Eagles International Chairman the Honorable Randy Avon. The Global Eagles is a group of diplomats, investment bankers, CEOs, University Presidents, investors and top international executives who gather regularly to network, present global projects to a group of seasoned peers, and to promote best leadership practices.
“I am truly honored to receive the Global Eagles Business Leader of the Year award,” said Chuck Arnold, Chairman and CEO of Stemtech. “The Global Eagles community is a distinguished group that includes top leaders in business, the investment community, government and academia. The impact that this organization and its members have had on international development and infrastructure is hard to overstate. I continue to enjoy the camaraderie and friendship of fellow Global Eagles members, and I look forward to being a member for many years to come.”
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem®, OraStem® (Oral Health Care), and D-Fuze™ (EMF Blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on May 16th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investor Relations: Frank J. Pena, 908-675-0581,
